open access
99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair
Affiliations- Nuclear Medicine Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
open access
Abstract
Brain metastases of PTC are rare and occur in 0.1-5% of the patients, especially in the poorly differentiated types that usually fail to concentrate iodine. We present a rare case of PTC with probable brain metastasis in a 58-year-old woman with a history of poorly differentiated PTC that showed elevated Tg levels and no metastasis was detected in the whole-body iodine scan, despite the positive 99m Tc-octreotide scintigraphy. This imaging modality could be helpful as a diagnostic guide for radionuclide therapy with labeled somatostatin analogs in cases of thyroid carcinoma with elevated Tg levels and negative whole-body iodine scan.
Abstract
Brain metastases of PTC are rare and occur in 0.1-5% of the patients, especially in the poorly differentiated types that usually fail to concentrate iodine. We present a rare case of PTC with probable brain metastasis in a 58-year-old woman with a history of poorly differentiated PTC that showed elevated Tg levels and no metastasis was detected in the whole-body iodine scan, despite the positive 99m Tc-octreotide scintigraphy. This imaging modality could be helpful as a diagnostic guide for radionuclide therapy with labeled somatostatin analogs in cases of thyroid carcinoma with elevated Tg levels and negative whole-body iodine scan.
Keywords
Papillary thyroid carcinoma; 99m Tc-octreotide scintigraphy; whole-body iodine
About this articleTitle
99m Tc-Octreotide-Avid Brain Mass In A Patient With Poorly Differentiated Papillary Thyroid Carcinoma, Hope In Despair
Journal
Issue
Article type
Clinical vignette
Pages
49-50
Published online
2020-01-31
Page views
618
Article views/downloads
527
DOI
10.5603/NMR.2020.0011
Pubmed
Bibliographic record
Nucl. Med. Rev 2020;23(1):49-50.
Keywords
Papillary thyroid carcinoma
99m Tc-octreotide scintigraphy
whole-body iodine
Authors
Sara Shakeri
Parinaz Jahanpanah
Ghasemali Divband
Toktam Massoudi
Kamran Aryana
References (8)- Tsuda K, Tsurushima H, Takano S, et al. Brain metastasis from papillary thyroid carcinomas. Mol Clin Oncol. 2013; 1(5): 817–819.
- Lowe VJ, Mullan BP, Hay ID, et al. 18F-FDG PET of patients with Hürthle cell carcinoma. J Nucl Med. 2003; 44(9): 1402–1406.
- Zhang H, Zeng L, Liang C, et al. Successful treatment of Hurthle cell thyroid carcinoma with lung and liver metastasis using docetaxel and cisplatin. Jpn J Clin Oncol. 2012; 42(11): 1086–1090.
- Khan S, Sharibi A, Neff R, et al. Metastatic Hürthle cell carcinoma: a unique case report and review of the literature. Endocr Pract. 2005; 11(4): 285–289.
- Pryma DA, Schöder H, Gönen M, et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006; 47(8): 1260–1266.
- Shinto AS, Kamaleshwaran KK, Mallia M, et al. Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. World J Nucl Med. 2015; 14(2): 101–108.
- Haslinghuis LM, Krenning EP, De Herder WW, et al. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001; 24(6): 415–422.
- Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996; 81(7): 2541–2544.
